Calliditas Therapeutics AB (publ)
SSE:CALTX.ST
107.8 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,206.888 | 802.879 | 229.347 | 0.874 | 184.829 | 0 | 0 | 0.497 | 0.478 |
| Cost of Revenue
| 77.057 | 15.201 | 0 | 0 | 0 | 0.051 | 0.051 | 56.517 | 51.389 |
| Gross Profit
| 1,129.831 | 787.678 | 229.347 | 0.874 | 184.829 | -0.051 | -0.051 | -56.02 | -50.911 |
| Gross Profit Ratio
| 0.936 | 0.981 | 1 | 1 | 1 | 0 | 0 | -112.716 | -106.508 |
| Reseach & Development Expenses
| 499.535 | 414.749 | 357.485 | 241.371 | 149.826 | 99.26 | 0.384 | 40.277 | 36.892 |
| General & Administrative Expenses
| 332.991 | 259.469 | 210.63 | 102.76 | 62.882 | 133.146 | 84.603 | 56.405 | 51.278 |
| Selling & Marketing Expenses
| 727.74 | 515.19 | 179.603 | 38.964 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1,014.693 | 774.659 | 390.232 | 141.724 | 62.882 | 133.146 | 84.603 | 56.405 | 51.278 |
| Other Expenses
| -7.11 | 20.212 | 6.085 | 0 | 0 | 0.051 | 0.051 | 0.112 | 0.111 |
| Operating Expenses
| 1,514.228 | 1,209.62 | 753.802 | 383.095 | 212.708 | 133.197 | 84.654 | 56.517 | 51.389 |
| Operating Income
| -384.397 | -421.943 | -524.456 | -379.72 | -28.019 | -132.482 | -84.509 | -56.02 | -50.911 |
| Operating Income Ratio
| -0.319 | -0.526 | -2.287 | -434.462 | -0.152 | 0 | 0 | -112.716 | -106.508 |
| Total Other Income Expenses Net
| -72.62 | 12.526 | 11.083 | -56.431 | -4.482 | 1.15 | 0.104 | 0.611 | 0.384 |
| Income Before Tax
| -457.017 | -409.417 | -513.373 | -436.151 | -32.501 | -132.049 | -86.794 | -56.912 | -51.014 |
| Income Before Tax Ratio
| -0.379 | -0.51 | -2.238 | -499.029 | -0.176 | 0 | 0 | -114.511 | -106.724 |
| Income Tax Expense
| 9.168 | 2.851 | -3.836 | 0.36 | 0.077 | 0.441 | 2.244 | 1.008 | 0.009 |
| Net Income
| -466.185 | -412.268 | -509.537 | -436.511 | -32.578 | -132.049 | -86.794 | -56.912 | -51.014 |
| Net Income Ratio
| -0.386 | -0.513 | -2.222 | -499.441 | -0.176 | 0 | 0 | -114.511 | -106.724 |
| EPS
| -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -2.54 | -2.91 | -0.86 | -0.77 |
| EPS Diluted
| -8.69 | -7.78 | -10.02 | -9.73 | -0.88 | -2.54 | -2.91 | -0.86 | -0.77 |
| EBITDA
| -367.803 | -421.942 | -524.455 | -378.851 | -25.13 | -133.14 | -84.603 | -56.403 | -51.278 |
| EBITDA Ratio
| -0.305 | -0.526 | -2.287 | -433.468 | -0.136 | 0 | 0 | -113.487 | -107.276 |